TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00984269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tourniquet Use
Description: Patients undergoing hand/wrist surgery with or without a tourniquet
Study: NCT00383435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol MDI
Description: Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI twice a day for 26 weeks
Study: NCT01691300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT PET/CT
Description: Old tracer but new indication
Study: NCT00902200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: See arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: See arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: See arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-12286 vehicle
Description: See arms
Study: NCT02942160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Study: NCT02660944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: RNase-Fc fusion protein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study: NCT03284268

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: VCN-01 intravitreal injection
Study: NCT04287062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Dual orexin receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Weight and color matched placebo
Study: NCT03649906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized Localization Technique
Description: The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
Study: NCT01635127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150mg s.c.
Study: NCT03799562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as pregnenolone (active study medication), except placebo dispensed.
Study: NCT03319927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPM educational workshop and consultation
Description: The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPM educational workshop and consultation
Description: The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
Study: NCT00548782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic diet
Description: diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADA ( American Diabetes Association) recommended diet
Description: diet
Study: NCT02341248

Intervention type: OTHER
Intervention: Exclusive Enteral Nutrition (EEN)
Description: 8 week standard course of treatment with EEN

Intervention type: OTHER
Intervention: Exclusive Enteral Nutrition (EEN)
Description: 8 week standard course of treatment with EEN
Study: NCT04242316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral arm training
Description: Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
Study: NCT04331327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allogenic lyophilized growth factors
Description: Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
Study: NCT03269591

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)

Intervention type: DRUG
Group type: OTHER
Intervention: diclofenac tablets
Description: drugs

Intervention type: DRUG
Group type: OTHER
Intervention: diclofenac tablets
Description: drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac tablets
Description: drugs

Intervention type: DRUG
Group type: OTHER
Intervention: diclofenac tablets
Description: drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac tablets
Description: drugs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual analogue scale
Description: a graphic rating scale

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual analogue scale
Description: a graphic rating scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue scale
Description: a graphic rating scale

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual analogue scale
Description: a graphic rating scale
Study: NCT01635127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Constituent of canakinumab
Study: NCT00996918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 m/kg
Description: I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study: NCT03269591

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Description: a graphic rating scale

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Progesterone blood level
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Progesterone blood level
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone blood level
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Progesterone blood level
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progesterone blood level
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Menstrual symptom questionnaire
Description: questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Menstrual symptom questionnaire
Description: questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Menstrual symptom questionnaire
Description: questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Menstrual symptom questionnaire
Description: questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Menstrual symptom questionnaire
Description: questionnaire
Study: NCT00397423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Description: Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: NS 1ml iH Qd\*5 days, 3 months interval for 4 times
Study: NCT03549845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program
Description: Cardiovascular disease prevention and health promotion
Study: NCT00629629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Advice
Description: Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness.
Study: NCT01832688

Intervention type: OTHER
Intervention: Programmatic prenatal care optimization
Description: To further integrate and improve nutrition-related services and messages in the prenatal care package.
Study: NCT03345953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP 1.4979
Description: Double blind versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind versus placebo
Study: NCT03554473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
Study: NCT03248778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: disclosure-support counseling intervention
Description: The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
Study: NCT00391092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100mg/m2 iv every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100mg/m2 iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
Study: NCT04329013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral Position during intervention
Description: Left lateral position during EGD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position during intervention
Description: Prone position during EGD
Study: NCT02591316

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT02282826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT03526913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP: autologous platelet-rich plasma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STSG
Description: skin graft: Split Thickness Skin Grafting (STSG)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STSG
Description: skin graft: Split Thickness Skin Grafting (STSG)
Study: NCT00701051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: 24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Detraining (cessation of exercise)
Description: Cessation of exercise for 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detraining (cessation of exercise)
Description: Cessation of exercise for 2 weeks
Study: NCT04112849

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of S3 heart sound
Description: S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
Study: NCT02923037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Complete guided and home yoga sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tape measurement of arm
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ldex measurement of arms
Study: NCT02073968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-adjusted IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo PET-adjusted IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-adjusted IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study: NCT03892941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaged based fitting
Description: Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
Study: NCT04363905

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg lactose per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 20 mg per day of elemental iron for 6 weeks
Study: NCT03532789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal patch
Description: One patch with medicine should be applied to the skin every other day within two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: One patch without medicine should be applied to the skin every other day within two weeks
Study: NCT03956602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzels
Description: To examine postprandial responses of pretzel consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazil nuts
Description: To examine postprandial responses of Brazil nut consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potato chips
Description: To examine postprandial responses of potato chip consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed nuts
Description: To examine postprandial responses of mixed nut consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White bread
Description: To examine postprandial responses of white bread consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried mango
Description: To examine postprandial responses of dried mango consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango fruit
Description: To examine postprandial responses of fresh mango consumption
Study: NCT02745626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appliance
Description: Orthodontic appliance to carry out orthodontic tooth movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appliance
Description: Orthodontic appliance to carry out orthodontic tooth movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appliance
Description: Orthodontic appliance to carry out orthodontic tooth movement.
Study: NCT02005341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOSS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Study: NCT02647359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ataluren
Description: Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study: NCT01731171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: Probiotic Supplement 1 tablet by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inert Compound
Description: Probiotic identical placebo 1 tablet by mouth daily
Study: NCT03795844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction Nathanson retractor
Description: liver retractor will be used for the retraction of left lobe of liver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction snake retractor
Description: liver retractor will be used for the retraction of left lobe of liver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction fan retractor
Description: liver retractor will be used for the retraction of left lobe of liver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction laparoscopic grasper
Description: laparoscopic grasper without any special tools
Study: NCT03310541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
Study: NCT01884298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil(Ultiva)
Description: remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural infusing 2% lidocaine
Description: epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia